Popular Gemcitabine News and Current Events

Popular Gemcitabine News and Current Events, Gemcitabine News Articles.
Sort By: Most Relevant | Most Recent
Page 1 of 6 | 208 Results
Vitamin A may help improve pancreatic cancer chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London. The promising initial results have led to the potential treatment being tested in a new clinical trial. (2016-05-24)

Certain factors may predict lung cancer patients' response to chemotherapy
In a retrospective analysis of 73 lung squamous cell carcinoma patients treated with the chemotherapy regimen of gemcitabine plus cisplatin, higher body mass index and younger age were linked with longer progression-free survival, the length of time that a patient lives with cancer but it does not get worse. Patients with better response to treatment and higher body mass index had longer overall survival in the Thoracic Cancer analysis. (2018-01-10)

Dialing up chemotherapy for pancreatic cancer with ultrasound
Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called 'sonoporation' with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed. They report some initial results at this week's ASA's 171st meeting in Salt Lake City. (2016-05-25)

DSI professor conducts research to combat pancreatic cancer
Tal Danino, a professor at the Data Science Institute, is conducting research that could help scientists combat the most lethal of cancers: pancreatic cancer. In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug -- Gemcitabine -- most commonly used to treat patients who have pancreatic cancer. (2017-10-05)

Significant survival gains from neoadjuvant chemotherapy for high-risk soft tissue sarcoma
Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial presented today at the ESMO 2016 Congress in Copenhagen. (2016-10-10)

Cannabinoid improves survival rates of mice with pancreatic cancer
Mice with pancreatic cancer that were treated with a naturally occurring constituent of medicinal cannabis alongside chemotherapy, survived almost three times longer than those treated with chemotherapy alone, a new study reports. (2018-07-30)

Simple post-surgery step reduces bladder cancer recurrence
In the latest issue of JAMA, SWOG researchers show that flushing the bladder with a common chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning. (2018-05-08)

How bacteria hinder chemotherapy
Scientists find bacteria in pancreatic tumors that metabolize a common drug. (2017-09-18)

The 'immuno revolution': Turning up the heat on resistant tumors
A promising class of drugs known as CD40 monoclonal antibodies could be the spark needed to light the fire in the immune system of patients who don't respond to the newer cancer immunotherapies. Robert H. Vonderheide, M.D., D.Phil., director of the Abramson Cancer Center at the University of Pennsylvania and an internationally renowned cancer immunotherapy expert, makes the case for the drugs in a new perspective piece published this week in Cancer Cell. (2018-04-09)

IDIBELL researchers successfully test a new combination therapy in sarcomas
Researchers of the Sarcoma group of the Oncobell program -- Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults. (2018-01-16)

New therapeutic gel shows promise against cancerous tumors
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results in animal models so far suggest this approach could one day ramp up therapeutic benefits for patients bearing tumors or after removal of the primary tumors. (2018-02-21)

Bladder Cancer Funding Analyzer launched on bladder cancer website
Bladder Cancer (BLC) is proud to announce the launch of the Bladder Cancer Funding Analyzer (BCFA) on the BLC website. It is a free service that is part of a new suite of online features that have been designed to serve the needs of the bladder cancer research community. (2017-02-16)

Drug for pancreatic cancer developed by college of pharmacy researchers
University of Houston researchers have developed a new medicine that can inhibit two of the major pathways of pancreatic cancer. The new synthetic compound is based on a type of sea sponge. (2018-09-11)

Chemotherapy with chemoradiation for pancreatic cancer has small survival benefit
The addition of the drug gemcitabine with chemoradiation for the treatment of patients who had surgery for pancreatic cancer was associated with a survival benefit, although this improvement was not statistically significant, according to a study in the March 5 issue of JAMA. (2008-03-04)

Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival. (2008-04-25)

Targeting old bottleneck reveals new anticancer drug strategy
The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists at Winship Cancer Institute of Emory University have identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts. (2019-07-22)

Toughest breast cancer may have met its match
Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these patients with traditional chemotherapy drugs that only show long-term effectiveness in 20 percent of women with triple-negative breast cancer. (2014-12-08)

Moffitt researchers compare chemotherapy regimens for best outcomes in invasive bladder cancer
Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder. But which type of chemotherapy leads to the best outcomes in terms of complete response rates or cancer control? Moffitt Cancer Center researchers examined data from more than 800 surgical patients with advanced bladder cancer. The results, published online by JAMA Oncology, show higher likelihoods of complete response or down-staging associated with a chemotherapeutic combination called ddMVAC. (2018-08-31)

New drug achieves pancreatic cancer tumor remission and prevents recurrence
Pancreatic cancer remains one of the deadliest cancers, but researchers may have found a combination therapy to reduce cancer stem cells and stop pancreatic cancer growth. Results will be presented at the American Association for Cancer Research 100th Annual Meeting 2009. (2009-04-19)

Comparing cancer drug effectiveness from cells to mice to man
Dartmouth researchers who studied the cancer drug gemcitabine in cell culture, mouse models and humans have shown that the drug, at administered (tolerated) dose, arrests cell growth during cancer progression. This information can lead to better understanding how gemcitabine can be combined with other drugs at identified phases to more effectively treat cancer. (2017-09-06)

Study establishes new standard of care for pancreatic cancer patients
A combination of two chemotherapy drugs -- gemcitabine and capecitabine -- should be the new standard of care for pancreatic cancer patients who have had surgery to remove their tumor. (2017-01-24)

EGLN inhibitor protects normal tissue and enables RT in mouse model of pancreatic cancer
Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer. (2019-04-30)

Study evaluates efficacy and safety of pancreatic cancer treatment
In a new study published in the Journal of Clinical Oncology, Manuel Hidalgo, MD, PhD, and colleagues conducted a phase I/II trial designed to evaluate the efficacy and safety of nab-paclitaxel given in combination with gemcitabine in patients with pancreatic cancer and reduced health status. (2018-12-12)

TGen-HonorHealth study: High rate of tumor shrinkage among pancreatic cancer patients
Adding cisplatin to standard gemcitabine/nab-paclitaxel drug treatment provided a very high rate of tumor shrinkage for patients with advanced pancreatic cancer, according to the results of a pilot clinical trial conducted by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen). These statistically significant and clinically meaningful improvements in overall response and survival rates resulted from a phase Ib/II clinical study performed at the HonorHealth Research Institute, a partnership of HonorHealth and TGen. (2017-04-25)

Gene-regulatory factors shown to improve pancreatic cancer response to chemotherapy
TMDU researchers revealed that, in pancreatic cancer, the microRNAs miR-509-5p and miR-1243 can promote E-cadherin expression and thereby reduce the likelihood of cells undergoing epithelial-mesenchymal transition, or indeed reverse this transition. This ability to stop cells from adopting a phenotype linked to high migration and invasiveness was also shown to synergistically increase the cancer cell-killing efficacy of gemcitabine, which is promising for developing more effective combinatorial treatments for pancreatic cancer. (2017-08-01)

New approach improves five-year survival for pancreatic cancer patients
A University of Liverpool (UK) led clinical trial has been successful in prolonging survival for pancreatic cancer patients by at least five years as a result of a combination of chemotherapy drugs. (2017-01-24)

Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after four months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer. (2016-05-03)

Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer (NSCLC), shows a randomised study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich. (2018-10-21)

Tumor-associated immune cells hinder frontline chemotherapy drug in pancreatic cancer
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found. (2019-03-26)

Lung cancer survival rates improved through use of individualized chemotherapy
Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing knowledge, a study published in the September edition of the Journal of Thoracic Oncology, analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer based on the histoculture drug response assay. (2010-09-01)

M. D. Anderson examines use of toad venom in cancer treatment
Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from the University of Texas M. D. Anderson Cancer Center. (2009-09-24)

Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
Giving pancreatic cancer patients the chemotherapy drug gemcitabine after surgery delays progression of the disease by about six months, according to new research by Japanese scientists. (2007-09-27)

Modified flu virus can 'resensitize' resistant pancreatic cancer cells to chemotherapy
A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London (QMUL). (2016-04-14)

Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven
In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive. (2016-04-08)

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer. The phase II NRG Oncology NRG-RTOG 0712 trial evaluated two regimens. One was the prior RTOG standard using 5-flourouracil and cisplatin with twice daily radiation (FCT), and the other a regimen of gemcitabine and daily radiation (GD) which had demonstrated efficacy in single institution clinical trials. (2020-10-26)

Stanford researchers develop new compound to reduce tumor growth
Researchers at Stanford found that a new cell surface receptor they created is effective at inhibiting cancer growth in mice. (2016-11-28)

New cancer vaccine extends progression-free survival in patients with advanced lung cancer
A Phase 2 trial, published online first in the Lancet Oncology, has shown that combining standard platinum-based chemotherapy with the new cancer vaccine TG4010 enhances the effect of chemotherapy and slows down the progression of advanced non-small-cell-lung cancer, the most common type of lung cancer, compared with chemotherapy alone. (2011-10-21)

Treatment based On BRCA1 level does not increase survival of stage II/III NSCLC N+ resected patients
Research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy treatment based on their specific BRCA1 expression levels, as opposed to providing the standard treatment, did not increase overall survival rates among those patients who received individualized CT treatment. Dr. Bartomeu Massuti of Alicante University Hospital in Spain presented his findings today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. (2017-10-16)

Nanoparticle drug delivery technique shows promise for treating pancreatic cancer
Veterans Affairs researchers have designed a new way to deliver pancreatic cancer drugs that could make fighting the disease much easier. (2021-01-28)

Researchers found that certain anti-influenza compounds also inhibit Zika virus infection
Researchers from the University of Helsinki have shown that three anti-influenza compounds effectively inhibit Zika virus infection in human cells. The results provide the foundation for development of the broad-spectrum cell-directed antivirals or their combinations for treatment of Zika and other emerging viral diseases. (2017-01-16)

Page 1 of 6 | 208 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.